Abstract
Objectives:To study the therapeutic effects of combined tamsulosin hydrochloride and terazosin treatment for patients with chronic prostatitis Type-III b.Methods:This study involved 180 patients with chronic prostatitis Type-III b treated between January 2018 and December 2020 conducted at Nanhua Hospital Affiliated to Nanhua University. Patients were randomly divided into two equal groups: one receiving oral terazosin hydrochloride tablets only (control group), and one orally receiving both tamsulosin hydrochloride sustained-release tablets and terazosin hydrochloride tablets (observation group). Outcome measurements included symptom scoring, inflammatory cytokine levels, as well as white blood cell and lecithin body counts in the prostatic fluid.Results:After 30 days of treatment, the observation group showed greater treatment effectiveness (86.67% vs. 73.33%, P<0.05). QLS, USS, PS, and NIH-CPSI symptom scores were lower in the observation group than the control group (P<0.05). No differences in adverse event distribution and incidence were noted. EPS IL-2 increased more in the observation group, while PGE-2, MIP-1α, and MIP-2 decreased more in the observation group. WBC levels decreased more in the observation group, while lecithin body levels increased more in the observation group.Conclusion:The combination of tamsulosin hydrochloride and terazosin for the treatment of patients with chronic prostatitis Type-III b has a significant effect. This approach reduced patient symptoms, lowered inflammatory biomarkers, and generally improved quality of life. This approach appears to have clinical value worthy of future investigation.
Highlights
Chronic prostatitis, defined as a non-bacteriarelated chronic inflammation of the prostate tissue, is caused by a variety of factors
Chronic prostatitis is often accompanied by elevated prostatic secretions, inflammatory cells, prostate hyperplasias and other symptoms.[1]
QLS, USS, PS, and NIH-CPSI symptom scores were similar among the control and observation groups
Summary
Chronic prostatitis ( known as Type-III clinical prostatitis), defined as a non-bacteriarelated chronic inflammation of the prostate tissue, is caused by a variety of factors. Pak J Med Sci March - April 2022 Vol 38 No 3 www.pjms.org.pk 595 are commonly used to treat chronic prostatitis, resulting in improved maximum flow rate as well as reduced dysuria and urodynia.[3,4] While they are well tolerated, using a single drug for a long course of treatment can have unclear effects on drug efficacy.[5] Tamsulosin blocks adrenoreceptors around the prostate, relaxes smooth muscle, relieves urethral spasm, and improves dysuria and urinary frequency.[6] In this study, tamsulosin hydrochloride and terazosin were used to treat patients with chronic prostatitis Type-III b, and the clinical efficacy and the changes of immune mediators in prostatic fluid were investigated
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
